Log In

Forgot Password?


Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Creatine Kinase in SARS-CoV-2-Related Encephalopathy as a Prognostic Biomarker for Post-Acute Sequelae of COVID-19 (PASC)
Neuromuscular and Clinical Neurophysiology (EMG)
P9 - Poster Session 9 (5:30 PM-6:30 PM)

Elevated CK levels have been demonstrated as a poor prognostic factor of outcomes in acute COVID-19 infection but its role as a marker of PASC is unclear.

To investigate whether creatine kinase is a prognostic factor in SARS-CoV-2 related encephalopathy in development of PASC.

A retrospective chart review was performed on hospitalized encephalopathic patients who developed COVID-19 infection during March-May of 2020 at an urban tertiary care center. Patients were divided into two subgroups according to elevated CK levels (E-CK) vs non-elevated CK levels (N-CK) with elevated defined as >200 u/L. Charts were analyzed for patients who had follow-up between 4 weeks and 1 year from initial visit to analyze subsequent development of new or persisting respiratory, cardiac, renal, or neurological symptoms to determine incidence of PASC. 

Of the 43 encephalopathic COVID-19 infection patients reviewed, 25 and 18 patients were found to be in the E-CK and N-CK groups, respectively (average serum CK level of 1485 u/L vs 87.11 u/L, p = 0.0026). Among the E-CK group, 14 patients (56%) had follow-up at least 4 weeks post admission in the outpatient setting vs 13 patients (72.22%) in the N-CK group (p > 0.05), with an average total follow up time of 477.37 days post initial admission in the E-CK group and 466.7857 days for N-CK (p > 0.05). In the follow-up E-CK group, 6 patients (42.85%) reported any one of the PASC symptoms whereas in the follow-up N-CK group, 9 patients (69.23%) reported any one of the PASC symptoms. (RR = 0.73, 95% CI [0.32-1.69], p = 0.47).

Encephalopathic patients who had elevated CK levels on COVID-19 infection admission did not have an increased risk of developing PASC. Work is in progress to confirm these findings by expanding sample size, increasing follow up time, and stratifying for confounding factors.
Iqra Faiz
Miss Faiz has nothing to disclose.
Narjis Jaffry, Other Miss Jaffry has nothing to disclose.
Shriya Mandava, Other Ms. Mandava has nothing to disclose.
Mustafa Jaffry Mr. Jaffry has nothing to disclose.
Ronak Uday Trivedi Mr. Trivedi has nothing to disclose.
Kranthi Kiran Mandava Mr. Mandava has nothing to disclose.
Anam Khalid Shaikh (New Jersey Medical School) Miss Shaikh has nothing to disclose.
Kazim Jaffry Mr. Jaffry has nothing to disclose.
Muhammed Ors Mr. Ors has nothing to disclose.
Pratibha Surathi, MD (Rutgers New Jersey Medical School) Dr. Surathi has nothing to disclose.
Toluwalase Oluwakemi Tofade, MBBS (Medstar) Dr. Tofade has nothing to disclose.
Evan Huff, MD Mr. Huff has nothing to disclose.
Sviatoslav Redko, MD (Conway Medical Center) Dr. Redko has nothing to disclose.
Nizar Souayah, MD, FAAN Dr. Souayah has received publishing royalties from a publication relating to health care.